Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo

Neuropsychopharmacology

Volumn 30, Issue 4, 2005, Pages 792-799

  Hunter, Aimee M ^a,b   Leuchter, Andrew F ^a,b   Morgan, Melinda L ^a,b   Cook, Ian A ^a,b   Abrams, Michelle ^a,b   Siegman, Barbara ^a,b   DeBrota, David J ^a,b   Potter, William Z ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressant medication; Cordance; EEG; Placebo effect; Randomized controlled trial; Side effects

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; VENLAFAXINE;

ADULT; ARTICLE; BRAIN FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERVIEW; MALE; NORMAL HUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; BRAIN MAPPING; CAUSALITY; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MIDDLE AGED; PLACEBO EFFECT; PREFRONTAL CORTEX; REFERENCE VALUES; SEROTONIN UPTAKE INHIBITORS;

EID: 15444378006     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300652     Document Type: Article

References (49)

1. Ader R (1997). The role of conditioning in pharmacotherapy. In: Harrington A (ed). The Placebo Effect: An Interdisciplinary Exploration. Cambridge University Press: Cambridge, MA. pp 138-165.
2. Anderson IM, Tomenson BM (1995). Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 310: 1433-1438.
3. Asada H, Fukudea Y, Tsunoda S, Yamaguchi M, Tonoike M (1999). Frontal midline theta rhythms reflect alternative activation of prefrontal cortex and anterior cingulate cortex in humans. Neurosci Lett 274: 29-32.
4. Barge-Schaapveld DQ, Nicolson NA (2002). Effects of antidepressant treatment on the quality of daily life: an experience sampling-study. J Clin Psychiatry 63: 477-485.
5. Barsky AJ, Goodson JD, Lane RS, Cleary PD (1988). The amplification of somatic symptoms. Psychosom Med 50: 510-519.
6. Barsky AJ, Saintfort R, Rogers MP, Borus JF (2002). Nonspecific medication side effects and the nocebo phenomenon. JAMA 287: 622-627.
7. Benedetti F, Polio A, Lopiano L, Lanotte M, Vighetti S, Rainero I (2003). Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 23: 4315-4323.
8. Brenner RP, Ulrich RF, Reynolds CF (1995). EEG spectral findings inhealthy elderly men and women - sex differences. Electroencephalogr Clin Neurophysiol 94: 1-5.
9. Cook IA, Leuchter AF (2001). Prefrontal changes and treatment response prediction in depression. Semin Clin Neuropsychiatry 6: 113-120.
10. Cook IA, Leuchter AF, Morgan M, Witte E, Stubbeman WF, Abrams M et al (2002). Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 27: 120-131.
11. Cook IA, Leuchter AF, Uijtedehaage SHJ, Holschneider D, Osato S, Abrams M et al (1998a). Altered cerebral energy utilization in late life depression. J Affect Disord 49: 89-99.
12. Cook IA, Leuchter AF, Witte E, Abrams M, Uijtdehaage SH, Stubbeman W et al (1999). Neurophysiologic predictors of treatment response to fluoxetine in major depression. Psychiatry Res 85: 263-273.
13. Cook IA, O'Hara R, Uijtdehaage SH, Mandelkern M, Leuchter AF (1998b). Assessing the accuracy of topographic EEG mapping for determining local brain function. Electroencephalogr Clin Neurophysiol 107: 408-414.
14. Davis C, Ralevski E, Kennedy SH, Neitzert C (1995). The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: a study of healthy male and female volunteers. J Clin Psychopharmacol 15: 347-352.
15. Eysenck HJ, Eysenck SBG (1991). Manual of the Eysenck Personality Scales. Hodder & Stoughton: London.
16. First MB, Spitzer RL, Gibbom M, Williams J (1994). Structured Clinical Interview for Axis IDSM-IV Disorders - Patient Edition (SCID-I/P, version 2.0). Biometrics Research Department, NY State Psychiatric Institute: New York.
17. Flaten MA, Simonsen T, Olsen H (1999). Drug-related information generates placebo and nocebo responses that modify the drug response. Psychosom Med 61: 250-255.
18. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E et al (2003). Adverse drug events in ambulatory care. N Engl J Med 348: 1556-1564.
19. Greenberg BD, Li Q, Lucas FR, Hu S, Sirota LA, Benjamin J et al (2000). Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population. Am J Med Genet 96: 202-216.
20. Greer MM, Kremer C, Rodrigues HE, Schatzberg AF (2003). Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160: 1830-1835.
21. Hahn RA (1997). The nocebo phenomenon: concept, evidence, and implications for public health. Prev Med 26: 607-611.
22. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
23. Ishii R, Shinosaki K, Ukai S, Inouye T, Ishihara T, Yoshimine T et al (1999). Medial prefrontal cortex generates frontal midline theta rhythm. Neuroreport 10: 675-679.
24. Jewett DL, Fein G, Greenberg MH (1990). A double-blind study of symptom provocation to determine food sensitivity. N Engl J Med 323: 429-433.
25. Kennedy WP (1961). The nocebo reaction. Medical World News 91: 203-205.
26. Kissel P, Barrucand D (1964). Placebos and Placebo Effect in Medicine (Placebos et effet placebo en medecine). Masson: Oxford, England, 240pp.
27. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J (1999). Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9: 435-443.
28. Leuchter AF, Cook IA, Greenwald SD, Kofol T (2004). Prefrontal EEG cordance correlates with anterior cingulate perfusion. Poster Presented at the Annual Meeting of the American Psychiatric Association, NR671.
29. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M (2002). Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 159: 122-129.
30. Leuchter AF, Newton TF, Cook IA, Walter DO, Rosenberg-Thompson S, Lachenbruch PA (1992). Changes in brain functional connectivity in Alzheimer's-type and infarct dementia. Brain 115: 1543-1561.
31. Leuchter AF, Uijtdehaage SHJ, Cook IA, O'Hara R, Mandelkern M (1999). Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res Neuroimaging 90: 125-140.
32. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL et al (1997). Cingulate function in depression: a potential predictor of treatment response. Neuroreport 8: 1057-1061.
33. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S et al (2002). The functional neuroanatomy of the placebo effect. Am J Psychiatry 159: 728-737.
34. McFadden Jr ER, Luparello T, Lyons HA, Bleecker E (1969). The mechanism of action of suggestion in the induction of acute asthma attacks. Psychosom Med 31: 134-143.
35. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I et al (1994). Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9: 47-53.
36. Montgomery SA, Kasper S (1995). Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol Suppl 4: 33-40.
37. Myers MG, Cairns JA, Singer J (1987). The consent form as a possible cause of side effects. Clin Pharmacol Ther 42: 250-253.
38. Ohayon MM, Schatzberg AF (2003). Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 60: 39-47.
39. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, Oakes TR, Larson CL, Abercrombie HC et al (2001). Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry 158: 405-415.
40. Pizzagalli DA, Oakes TR, Davidson RJ (2003). Coupling of theta activity and glucose metabolism in the human rostral anterior cingulate cortex: an EEG/PET study of normal and depressed subjects. Psychophysiology 40: 939-949.
41. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA (2002). A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics 2: 191-196.
42. Roscoe JA, Hickok JT, Morrow GR (2000). Patient expectations as predictor of chemotherapy-induced nausea. Ann Behav Med 22: 121-126.
43. Rosenzweig P, Brohier S, Zipfel A (1993). The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies. Clin Pharmacol Ther 54: 578-583.
44. Rush AJ (2001). Sequenced treatment alternatives to relieve depression (STAR*D) protocol. NIMH Contract GMO-010111. http://www.edc.gsph.pitt.edu/ stard/.
45. Sawamoto N, Honda M, Okada T, Hanakawa T, Kanda M, Fukuyama H et al (2000). Expectation of pain enhances responses to nonpainful somatosensory stimulation in the anterior cingulate cortex and parietal operculum/posterior insula: an event-related functional magnetic resonance imaging study. Neuroscience 20: 7438-7445.
46. Siegel S (2002). Explanatory mechanisms for placebo effects: Pavlovian conditioning. In: Guess HA, Kleinman A, Kusek JW, Engel LW (eds). The Science of the Placebo: Toward an Interdisciplinary Research Agenda. BMJ Books: London. pp 133-157.
47. Ueda K, Okamoto Y, Okada G, Yamashita H, Hori T, Yamawaki S (2003). Brain activity during expectancy of emotional stimuli: an fMRI study. Neuroreport 14: 51-55.
48. Ulrich G, Haug HJ, Fahndrich E (1994). Acute versus chronic EEG effects of maprotiline- and in clomipramine-treated depressive inpatients and the prediction of therapeutic outcome. J Affect Disord 32: 213-217.
49. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M et al (2003). Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology 48: 10-13.